Cefpodoxime

Identification

Name
Cefpodoxime
Accession Number
DB01416
Description

Cefpodoxime is an oral third generation cephalosporin antibiotic with effectiveness against most Gram positive and Gram negative bacteria. Commonly used to treat acute otitis media, pharyngitis, and sinusitis, cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime.

Type
Small Molecule
Groups
Approved, Vet approved
Structure
Thumb
Weight
Average: 427.455
Monoisotopic: 427.062024681
Chemical Formula
C15H17N5O6S2
Synonyms
  • Cefpodoxima
  • Cefpodoxime
  • Cefpodoximum
External IDs
  • RU 51807

Pharmacology

Indication

Indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms.

Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

Cefpodoxime is shown to be effective against most Gram positive and Gram negative bacteria, except Pseudomonas aeruginosa, Enterococcus, and Bacteroides fragilis.

Mechanism of action

Cefpodoxime is active against a wide spectrum of Gram-positive and Gram-negative bacteria. Cefpodoxime is stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and cephalosporins, due to their production of beta-lactamase, may be susceptible to cefpodoxime. Cefpodoxime is inactivated by certain extended spectrum beta-lactamases. The bactericidal activity of cefpodoxime results from its inhibition of cell wall synthesis. The active metabolite of cefpodoxime binds preferentially to penicillin binding protein 3, which inhibits production of peptidoglycan, the primary constituent of bacterial cell walls.

TargetActionsOrganism
APeptidoglycan synthase FtsI
inhibitor
Escherichia coli (strain K12)
Absorption

Cefpodoxime proxetil is a prodrug that is absorbed from the gastrointestinal tract and de-esterified to its active metabolite, cefpodoxime. Following oral administration of 100 mg of cefpodoxime proxetil to fasting subjects, approximately 50% of the administered cefpodoxime dose was absorbed systemically.

Volume of distribution
Not Available
Protein binding

22 to 33% in serum and from 21 to 29% in plasma.

Metabolism
Not Available
Route of elimination

Over the recommended dosing range (100 to 400 mg), approximately 29 to 33% of the administered cefpodoxime dose was excreted unchanged in the urine in 12 hours.

Half-life

2.09 to 2.84 hours

Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
  • Enteric bacteria and other eubacteria
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirCefpodoxime may decrease the excretion rate of Abacavir which could result in a higher serum level.
AbciximabThe therapeutic efficacy of Abciximab can be decreased when used in combination with Cefpodoxime.
AcarboseCefpodoxime may decrease the excretion rate of Acarbose which could result in a higher serum level.
AceclofenacCefpodoxime may decrease the excretion rate of Aceclofenac which could result in a higher serum level.
AcemetacinThe risk or severity of nephrotoxicity can be increased when Cefpodoxime is combined with Acemetacin.
AcenocoumarolThe risk or severity of bleeding can be increased when Cefpodoxime is combined with Acenocoumarol.
AcetaminophenCefpodoxime may decrease the excretion rate of Acetaminophen which could result in a higher serum level.
Acetylsalicylic acidThe risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Cefpodoxime.
AclidiniumCefpodoxime may decrease the excretion rate of Aclidinium which could result in a higher serum level.
AcrivastineCefpodoxime may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
  • Take on an empty stomach. Take at least 1 hour before or 2 hours after meals.

Products

Product Ingredients
IngredientUNIICASInChI Key
Cefpodoxime proxetil2TB00A1Z7N87239-81-4LTINZAODLRIQIX-FBXRGJNPSA-N
Cefpodoxime sodium3ULP5169B382619-04-3JNMXSNGAMPXCDR-XYNKDNFRSA-M
Product Images
International/Other Brands
Banan / Doxef
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
OreloxTabletOralSanofi AventisNot applicableNot applicableCanada flag
VantinGranule, for suspension50 mg/5mLOralPharmacia and Upjohn Company LLC1991-08-292007-10-29US flag
VantinTablet, film coated100 mg/1OralPharmacia and Upjohn Company LLC1991-08-292008-12-31US flag
VantinTablet, film coated200 mg/1OralPd Rx Pharmaceuticals, Inc.1991-08-292015-05-12US flag
VantinGranule, for suspension100 mg/5mLOralPharmacia and Upjohn Company LLC1991-08-292007-10-29US flag
VantinTablet, film coated200 mg/1OralPharmacia and Upjohn Company LLC1991-08-292010-03-31US flag
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Cefpodoxime ProxetilGranule, for suspension50 mg/5mLOralNorthStar Rx LLC2007-06-08Not applicableUS flag
Cefpodoxime ProxetilTablet, film coated200 mg/1OralNorth Star Rx Llc2009-08-122011-11-30US flag
Cefpodoxime ProxetilGranule, for suspension100 mg/5mLOralSandoz Inc2009-06-252019-07-31US flag
Cefpodoxime ProxetilTablet, film coated200 mg/1OralAcetris Health, Llc2007-06-112019-05-31US flag
Cefpodoxime ProxetilTablet, film coated100 mg/1OralAurobindo Pharma Limited2007-06-11Not applicableUS flag
Cefpodoxime ProxetilTablet, film coated200 mg/1OralNorthStar Rx LLC2007-06-11Not applicableUS flag
Cefpodoxime ProxetilTablet, film coated100 mg/1OralSandoz Inc2008-05-28Not applicableUS flag
Cefpodoxime ProxetilTablet, film coated100 mg/1OralOrchidPharma Inc2016-09-152019-11-30US flag
Cefpodoxime ProxetilTablet, film coated200 mg/1OralPutney Inc2008-05-282020-12-31US flag
Cefpodoxime ProxetilGranule, for suspension50 mg/5mLOralRising Pharmaceuticals, Inc.2007-06-08Not applicableUS flag
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more

Categories

ATC Codes
J01DD13 — Cefpodoxime
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as cephalosporins. These are compounds containing a 1,2-thiazine fused to a 2-azetidinone to for a oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid moiety or a derivative thereof.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Lactams
Sub Class
Beta lactams
Direct Parent
Cephalosporins
Alternative Parents
N-acyl-alpha amino acids and derivatives / 2,4-disubstituted thiazoles / 1,3-thiazines / 2-amino-1,3-thiazoles / Tertiary carboxylic acid amides / Heteroaromatic compounds / Secondary carboxylic acid amides / Amino acids / Azetidines / Dialkylthioethers
show 10 more
Substituents
1,3-thiazol-2-amine / 2,4-disubstituted 1,3-thiazole / Alpha-amino acid or derivatives / Amine / Amino acid / Amino acid or derivatives / Aromatic heteropolycyclic compound / Azacycle / Azetidine / Azole
show 25 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
cephalosporin, carboxylic acid (CHEBI:3504)

Chemical Identifiers

UNII
7R4F94TVGY
CAS number
80210-62-4
InChI Key
WYUSVOMTXWRGEK-HBWVYFAYSA-N
InChI
InChI=1S/C15H17N5O6S2/c1-25-3-6-4-27-13-9(12(22)20(13)10(6)14(23)24)18-11(21)8(19-26-2)7-5-28-15(16)17-7/h5,9,13H,3-4H2,1-2H3,(H2,16,17)(H,18,21)(H,23,24)/b19-8-/t9-,13-/m1/s1
IUPAC Name
(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
SMILES
[H][[email protected]]12SCC(COC)=C(N1C(=O)[[email protected]]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O

References

Synthesis Reference

Yatendra Kumar, Neera Tewari, Ram Aryan, Bishwa Rai, Hashim Nizar, "Process for the preparation of cefpodoxime acid." U.S. Patent US20050020561, issued January 27, 2005.

US20050020561
General References
Not Available
Human Metabolome Database
HMDB0015486
KEGG Drug
D07650
KEGG Compound
C08114
PubChem Compound
6335986
PubChem Substance
46504897
ChemSpider
4891496
BindingDB
50292251
RxNav
20489
ChEBI
3504
ChEMBL
CHEMBL1672
ZINC
ZINC000003830453
Therapeutic Targets Database
DAP000457
PharmGKB
PA164746385
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Cefpodoxime
AHFS Codes
  • 08:12.06.12 — Third Generation Cephalosporins
FDA label
Download (369 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentOtitis Media With Effusion1
3RecruitingTreatmentBacterial Sinusitis / Rhinosinusitis Acute / Sinus infection / Sinusitis / Sinusitis, Acute1
1CompletedTreatmentDiarrhea / Neoplasms1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentNeuroblastomas1
1CompletedTreatmentTumors, Solid2
0Unknown StatusTreatmentOsteomyelitis1
Not AvailableActive Not RecruitingOtherAnti-Bacterial Agents / Microbiota1
Not AvailableCompletedTreatmentUrinary Tract Infection1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Aurobindo Pharma Ltd.
  • Dispensing Solutions
  • Murfreesboro Pharmaceutical Nursing Supply
  • Northstar Rx LLC
  • Nucare Pharmaceuticals Inc.
  • Orchid Healthcare
  • PD-Rx Pharmaceuticals Inc.
  • Pfizer Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmacia Inc.
  • Public Health Department Seattle and King County
  • Putney Inc.
  • Ranbaxy Laboratories
  • Redpharm Drug
  • Sandoz
Dosage Forms
FormRouteStrength
Tablet, film coatedOral
Granule, for suspensionOral0.8 %
Tablet, film coatedOral100 MG
Tablet, film coatedOral200 MG
PowderParenteral40 MG/5ML
Powder, for suspensionOral40 MG/5ML
Tablet, coated100 MG
Tablet, coated200 MG
Granule, for suspensionOral100 mg/5mL
Granule, for suspensionOral50 mg/5mL
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral200 mg/1
Tablet, film coated200 mg
Tablet, coatedOral100 mg
Powder, for suspensionOral800 mg
SuspensionOral20 mg/ml
SuspensionOral50 mg/5ml
SuspensionOral40 mg/5ml
Granule40 mg
Tablet, film coated100 mg
Granule100 mg
Granule50 mg
Tablet, coated400 mg
PowderOral100 mg
PowderOral40 mg
PowderOral50 mg
TabletOral
GranuleOral40 mg/5ml
Granule, for suspensionOral40 MG/5ML
GranuleOral100 mg
Tablet, coatedOral200 mg
GranuleOral40 mg
GranuleOral50 mg
Prices
Unit descriptionCostUnit
Vantin 20 200 mg tablet Bottle194.37USD bottle
Vantin 20 100 mg tablet Bottle137.26USD bottle
Vantin 100 mg/5ml Suspension 100ml Bottle133.84USD bottle
Vantin 50 mg/5ml Suspension 100ml Bottle70.34USD bottle
Vantin 50 mg/5ml Suspension 50ml Bottle36.95USD bottle
Vantin 200 mg tablet9.67USD tablet
Cefpodoxime Proxetil 200 mg tablet7.02USD tablet
Cefpodoxime 200 mg tablet6.41USD tablet
Vantin 100 mg tablet6.33USD tablet
Cefpodoxime 100 mg tablet5.11USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.185 mg/mLALOGPS
logP0.05ALOGPS
logP-1.2ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)3.22ChemAxon
pKa (Strongest Basic)4.16ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area156.44 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity100.71 m3·mol-1ChemAxon
Polarizability39.9 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.5556
Blood Brain Barrier-0.984
Caco-2 permeable-0.7549
P-glycoprotein substrateSubstrate0.7587
P-glycoprotein inhibitor INon-inhibitor0.8753
P-glycoprotein inhibitor IIInhibitor0.6389
Renal organic cation transporterNon-inhibitor0.8645
CYP450 2C9 substrateNon-substrate0.8729
CYP450 2D6 substrateNon-substrate0.8183
CYP450 3A4 substrateSubstrate0.535
CYP450 1A2 substrateNon-inhibitor0.7905
CYP450 2C9 inhibitorNon-inhibitor0.8017
CYP450 2D6 inhibitorNon-inhibitor0.8895
CYP450 2C19 inhibitorNon-inhibitor0.7558
CYP450 3A4 inhibitorNon-inhibitor0.7875
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9144
Ames testNon AMES toxic0.8249
CarcinogenicityNon-carcinogens0.8656
BiodegradationNot ready biodegradable0.9863
Rat acute toxicity1.9732 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9764
hERG inhibition (predictor II)Non-inhibitor0.8162
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Peptidoglycan glycosyltransferase activity
Specific Function
Essential cell division protein that is required for the synthesis of peptidoglycan at the division septum (PubMed:1103132, PubMed:9614966). Catalyzes the synthesis of cross-linked peptidoglycan fr...
Gene Name
ftsI
Uniprot ID
P0AD68
Uniprot Name
Peptidoglycan synthase FtsI
Molecular Weight
63876.925 Da
References
  1. Boaretti M, Lleo MM, Canepari P: In vitro activity, beta-lactamase stability and PBP affinity of RU 51,746-2, the active metabolite of the new orally absorbed cephalosporin ester, RU 51807. J Chemother. 1991 Jan;3 Suppl 1:57-61. [PubMed:12041787]

Drug created on July 23, 2007 07:09 / Updated on October 21, 2020 01:55

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates